President Trump, Sec. Kennedy Jr. Launch Ambitious Initiative Targeting Autism Epidemic: New Therapeutic Pathways and Public Health Warnings Issued
WASHINGTON D.C. – September 22, 2025 – In a significant move to address escalating autism spectrum disorder (ASD) rates nationwide, President Donald J. Trump and U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. announced a comprehensive suite of bold actions today. The initiative targets a perceived epidemic, with recent national news highlighting that approximately 1 in 31 children in the U.S. are now affected by ASD, a substantial increase from previous decades. The multi-pronged strategy involves establishing a new therapeutic pathway, initiating a review of a common over-the-counter medication, and injecting substantial funding into autism research.
New Therapeutic Pathway Opens for Children with Cerebral Folate Deficiency
A cornerstone of today’s announcement is the U.S. Food and Drug Administration’s (FDA) action to update the label for leucovorin, a medication primarily used in cancer treatment and for certain anemias. This update aims to recognize leucovorin for treating cerebral folate deficiency (CFD), a neurological condition linked to difficulties in folate transport into the brain. Studies suggest that CFD can manifest with developmental delays, autistic features, seizures, and motor coordination problems. The FDA’s move establishes what is described as the first FDA-recognized therapeutic pathway for children with CFD and associated autistic symptoms, potentially offering benefits for speech-related deficits in a subset of affected children. Following this label change, state Medicaid programs are expected to cover leucovorin for the indication of ASD, expanding access for over half of American children who rely on these programs. The National Institutes of Health (NIH) also announced plans for confirmatory trials and further research into leucovorin’s impact, though officials caution it is not a cure for ASD.
Acetaminophen Safety Under FDA Review Amidst Ongoing Debate
In parallel, the FDA announced it is initiating the process for a safety label change for acetaminophen, commonly known as Tylenol and found in numerous other products. This review is prompted by clinical and laboratory studies suggesting a potential association between acetaminophen use during pregnancy and adverse neurodevelopmental outcomes, including later diagnoses of autism and ADHD. HHS will concurrently launch a nationwide public service campaign to inform families about these potential risks. However, this aspect of the announcement has been met with significant caution and criticism from the scientific and medical communities. While acknowledging studies showing an association, the FDA itself recognizes that a clear causal relationship has not been established, noting the existence of contrary studies and the risks associated with untreated fevers during pregnancy. Major medical organizations, including the American College of Obstetricians and Gynecologists (ACOG) and the American Academy of Pediatrics (AAP), have stated that high-quality research does not support a causal link and that acetaminophen remains the safest over-the-counter option for pain and fever relief during pregnancy, urging consultation with healthcare professionals. Kenvue, the manufacturer of Tylenol, has also pushed back, arguing that a label change would be an “unexplained departure” from the FDA’s long-standing position on the drug’s safety.
National Institutes of Health Boosts Autism Research with Data Science Initiative
To further unravel the complexities of autism, the NIH is launching the Autism Data Science Initiative (ADSI). This significant undertaking will allocate over $50 million to fund 13 research projects aimed at transforming the understanding of autism’s causes and prevalence. The initiative will leverage large-scale data resources, integrating genomic, epigenomic, clinical, and environmental factors through an “exposomics” approach. These projects will employ advanced methods like machine learning and analyze data from diverse sources, including clinical records and genetic databases, in collaboration with the autism community.
Addressing a Growing Public Health Concern
The urgency behind these actions is underscored by recent data from the CDC’s Autism and Developmental Disabilities Monitoring (ADDM) Network, which indicates that approximately 1 in 31 children aged 8 years were identified with ASD in 2022, an increase from 1 in 36 children just two years prior. The prevalence has surged dramatically since the early 2000s.
Conclusion
This recent announcement marks a significant governmental push to confront the rising rates of autism, introducing a novel therapeutic avenue for a specific subset of children and initiating a critical review of acetaminophen’s use during pregnancy. Coupled with a substantial investment in autism research, these actions signal a new era of focus on understanding and addressing the disorder’s multifaceted nature, aiming to provide hope and tangible support for millions of American families.
Related Posts
